TR200101927T2 - Etkin maddelerin geliştirilmiş bir şekilde verilmesini sağlayan bileşimler. - Google Patents

Etkin maddelerin geliştirilmiş bir şekilde verilmesini sağlayan bileşimler.

Info

Publication number
TR200101927T2
TR200101927T2 TR2001/01927T TR200101927T TR200101927T2 TR 200101927 T2 TR200101927 T2 TR 200101927T2 TR 2001/01927 T TR2001/01927 T TR 2001/01927T TR 200101927 T TR200101927 T TR 200101927T TR 200101927 T2 TR200101927 T2 TR 200101927T2
Authority
TR
Turkey
Prior art keywords
compositions
liquid
active ingredients
provide improved
improved delivery
Prior art date
Application number
TR2001/01927T
Other languages
English (en)
Inventor
Joseph Dobrozsi Douglas
Ii Jerry William Hayes
Jivanlal Desai Kishor
James Robbins Brian
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of TR200101927T2 publication Critical patent/TR200101927T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bulus, farmasötik olarak etkin maddelerin vücuda verilmesinin gelistirildigi bilesimlerle ilgilidir. Bu bilesimler farmasötik olarak etkin maddeleri susuz çözücü içinde içermektedirler. Bu bilesimler, agiz içine konulan ve neticede yutulan sivi iksirler seklini alabilmekte veya sivi-dolgulu damlalar, ölçümlü sivi dozlama düzenekleri, atomizörler ve sivi-salan, yenilebilir kapsüller araciligiyla uygulanabilmektedir.
TR2001/01927T 1999-01-11 2000-01-10 Etkin maddelerin geliştirilmiş bir şekilde verilmesini sağlayan bileşimler. TR200101927T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11537899P 1999-01-11 1999-01-11

Publications (1)

Publication Number Publication Date
TR200101927T2 true TR200101927T2 (tr) 2001-11-21

Family

ID=22361013

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01927T TR200101927T2 (tr) 1999-01-11 2000-01-10 Etkin maddelerin geliştirilmiş bir şekilde verilmesini sağlayan bileşimler.

Country Status (15)

Country Link
US (1) US6846495B2 (tr)
EP (1) EP1140093A2 (tr)
JP (1) JP2002534463A (tr)
KR (1) KR100511730B1 (tr)
CN (1) CN1203854C (tr)
AU (1) AU762366B2 (tr)
BR (1) BR0007445A (tr)
CA (1) CA2356881C (tr)
CO (1) CO5270007A1 (tr)
CZ (1) CZ20012491A3 (tr)
HU (1) HUP0105021A3 (tr)
NO (1) NO20013442L (tr)
PE (1) PE20001415A1 (tr)
TR (1) TR200101927T2 (tr)
WO (1) WO2000041693A2 (tr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1280515T3 (da) 2000-03-09 2007-06-11 Gw Pharma Ltd Farmaceutiske sammensætninger omfattende cannabis
PT1321140E (pt) * 2000-08-25 2005-06-30 Kowa Co Solucoes de ibuprofeno para o enchimento de capsulas e preparacoes de capsula
US7138133B2 (en) * 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
JP5607291B2 (ja) 2004-11-24 2014-10-15 メダ ファーマシューティカルズ インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
WO2006095363A2 (en) * 2005-02-01 2006-09-14 Troikaa Pharmaceuticals Ltd Injectable preparations of diclofenic and its pharmaceutically acceptable salts
ES2619161T3 (es) 2006-04-05 2017-06-23 Intercontinental Great Brands Llc Complejo de fosfato de calcio y sales en sistemas de suministro oral
AU2007235445B2 (en) 2006-04-05 2011-04-14 Intercontinental Great Brands Llc Calcium phosphate complex in acid containing confectionery
CN101478885A (zh) * 2006-06-29 2009-07-08 吉百利亚当斯美国有限责任公司 改进的用于连续成型中心填充胶基糖块的链式切割机
WO2009018158A1 (en) * 2007-07-27 2009-02-05 Cadbury Adams Usa Llc Method and apparatus for processing confectionery products
DE102007000521A1 (de) * 2007-10-18 2009-04-23 Renate Conrad Hustenpräparat
ES2465228T5 (es) † 2008-02-08 2022-03-18 Procter & Gamble Proceso para fabricar una bolsa soluble en agua
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
GB201215988D0 (en) * 2012-09-07 2012-10-24 Reckitt Benckiser Healthcare Int Ltd Pharmaceutical compositions comprising flurbiprofen
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
CA2969188C (en) * 2014-12-12 2023-05-02 Ari Healthcare Pvt. Ltd. A mouth freshener
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
US11234897B2 (en) * 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
CA3100314A1 (en) 2018-05-16 2019-11-21 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3085942A (en) * 1960-12-28 1963-04-16 Hoffmann La Roche Antitussive compositions and preparation
US4136163A (en) 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
CA1027347A (en) 1972-07-20 1978-03-07 David G. Rowsell Compounds having a physiological cooling effect and compositions containing them
SE7812207L (sv) 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
US4474985A (en) 1981-07-06 1984-10-02 Monsanto Company Purification of N-acetyl aminophenols
JPS5888334A (ja) 1981-11-20 1983-05-26 Takasago Corp ３−ｌ−メントキシプロパン−１、２−ジオ−ル
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
GB8629567D0 (en) 1986-12-10 1987-01-21 Boots Co Plc Therapeutic agents
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US4883660A (en) * 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5196486A (en) 1989-03-17 1993-03-23 Nalco Chemical Company Alkoxylated vinyl polymer demulsifiers
US5100898A (en) 1990-01-25 1992-03-31 Richardson-Vicks Inc. Antitussive liquid compositions containing dyclonine
US5196436A (en) 1990-10-31 1993-03-23 The Procter & Gamble Company Dextromethorphan antitussive compositions
CA2129676C (en) * 1990-10-31 1997-09-30 Ronald Lee Smith Dextromethorphan antitussive compositions
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
WO1994018970A1 (en) 1993-02-18 1994-09-01 Warner-Lambert Company Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents
US5505961A (en) 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
MX9602955A (es) 1994-01-24 1997-06-28 Procter & Gamble Procedimiento para solubizar activos farmaceuticos dificilmente solubles.
US5510389A (en) 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5846557A (en) * 1996-03-20 1998-12-08 Cumberland Packing Corporation Chewing gum containing cough suppressing agent
US5955098A (en) 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
ES2234010T3 (es) 1996-04-12 2005-06-16 Novadel Pharma Inc. Aerosol bucal polar.
SE9601528D0 (sv) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
WO1998052545A1 (en) 1997-05-22 1998-11-26 The Boots Company Plc Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
EP1952802A3 (en) 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule

Also Published As

Publication number Publication date
AU762366B2 (en) 2003-06-26
HUP0105021A2 (hu) 2002-05-29
HUP0105021A3 (en) 2003-02-28
BR0007445A (pt) 2001-10-16
EP1140093A2 (en) 2001-10-10
NO20013442D0 (no) 2001-07-11
AU2962700A (en) 2000-08-01
US20030139437A1 (en) 2003-07-24
CO5270007A1 (es) 2003-04-30
KR20010093255A (ko) 2001-10-27
CZ20012491A3 (cs) 2001-12-12
WO2000041693A2 (en) 2000-07-20
CA2356881A1 (en) 2000-07-20
CA2356881C (en) 2012-02-28
CN1203854C (zh) 2005-06-01
KR100511730B1 (ko) 2005-08-31
NO20013442L (no) 2001-09-11
WO2000041693A3 (en) 2000-11-30
CN1336823A (zh) 2002-02-20
JP2002534463A (ja) 2002-10-15
US6846495B2 (en) 2005-01-25
PE20001415A1 (es) 2001-01-05

Similar Documents

Publication Publication Date Title
TR200101927T2 (tr) Etkin maddelerin geliştirilmiş bir şekilde verilmesini sağlayan bileşimler.
TR200101929T2 (tr) Geliştirilmiş kararlılığa sahip bileşimler.
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
BR0213143A (pt) Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquileno
EP1365749A4 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS
EA200200126A1 (ru) Гидродинамически сбалансированная пероральная система доставки лекарства
AR022930A2 (es) MICROCAPSULAS, DE TIPO RESERVORIO, QUE CONTIENEN POR LO MENOS UN PRINCIPIO ACTIVO MEDICAMENTOSO Y/O NUTRITIVO (PA) CON EXCLUSION DEL ACIDO ACETILSALICILICO (ASA), DESTINADAS A LA ADMINISTRACION POR VIA ORAL, SU UTILIZACIoN Y FORMA FARMACEUTICA QUE COMPRENDE A DICHAS MICROCAPSULAS.
DE60312523D1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
EA200300045A1 (ru) Композиция и лекарственная форма для задерживаемого желудочного выделения алендроната и/или других бис-фосфонатов
NO953278D0 (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
TR200101928T2 (tr) Geliştirilmiş kararlılığa sahip bileşimler
JP5970189B2 (ja) 医薬調製物
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
TR200001761T2 (tr) Çoklu terapilerde aktif esasların tatbiki için bir çift kapsül.
HUP0301349A2 (hu) IL-11-tartalmú készítmények
AR098745A2 (es) Composición, kit y uso de compuestos quimioterapéuticos
BR0111678A (pt) Composições medicinais contendo derivados de propenona
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
MXPA04004907A (es) Composiciones de acetaminofen.
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
ATE314109T1 (de) Dosierbehälter für pulverförmige medikamente
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
NZ596881A (en) Phentermine liquid dosage form
MY133368A (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
WO2007062262A3 (en) Gelatinous medicament formulation and method of administration